Welcome to our dedicated page for VOLITIONRX SEC filings (Ticker: VNRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on VOLITIONRX's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into VOLITIONRX's regulatory disclosures and financial reporting.
VolitionRx Ltd reported that officer Rodney Gerard Rootsaert had 3,321 shares of common stock withheld and retained by the company for cancellation to cover tax obligations arising from the settlement of 7,908 restricted stock units that had been awarded in lieu of cash compensation. The filing specifies that no shares were sold by either the officer or VolitionRx in this transaction. After this tax-withholding event, Rootsaert directly holds 277,941 shares of common stock and indirectly is reported as having voting and dispositive control over 1,007,718 shares held by Concord International, Inc.
VolitionRx Ltd’s Chief Commercial Officer Gael Forterre had 2,283 shares of common stock withheld and cancelled by VolitionRx at $0.213 per share to cover tax obligations when 5,523 restricted stock units settled, and no shares were sold in the market. Following this tax-withholding disposition, he directly owns 336,589 common shares, with additional indirect holdings of 5,000 shares by his spouse and 32,500 shares managed by Armorica Partners, LLC.
VolitionRx Ltd reported an insider equity adjustment involving its General Counsel of Volition Diagnostics, Nicholas Plummer. A total of 5,867 shares of common stock were retained by VolitionRx for cancellation to cover tax withholding on the settlement of 12,483 restricted stock units that had been awarded in lieu of cash compensation. The filing notes that no shares were sold by Plummer or by VolitionRx in this transaction. Following this tax-withholding disposition, Plummer directly holds 414,270 shares of VolitionRx common stock.
Forterre Gael reported acquisition or exercise transactions in this Form 4 filing.
VolitionRx Ltd reported that Chief Commercial Officer Gael Forterre was awarded 149,000 restricted stock units (RSUs) of common stock under the 2024 Stock Incentive Plan in lieu of cash compensation. The RSUs are earned in twelve approximately equal monthly installments starting March 1, 2026, then remain subject to additional time-based vesting in a single installment on February 26, 2027, generally requiring continued service through each earning and vesting date. Upon vesting and settlement, he will receive one share of common stock for each earned and vested RSU. After this grant, he directly holds 338,872 common shares. Indirect holdings reported include 5,000 shares held by his spouse and 32,500 shares held by Armorica Partners, LLC, where he has voting and dispositive control but disclaims beneficial ownership except to the extent of his pecuniary interest.
Rubin Ethel reported acquisition or exercise transactions in this Form 4 filing.
VolitionRx Ltd director Ethel Rubin reported an equity award rather than a stock purchase or sale. On February 26, 2026, Rubin was granted 178,000 restricted stock units (RSUs) under the company’s 2024 Stock Incentive Plan in lieu of cash compensation. The RSUs are earned in twelve roughly equal monthly installments beginning February 1, 2026, then are scheduled to vest in a single installment on February 26, 2027, subject to Rubin’s continued service. Upon vesting and settlement, Rubin will receive one share of common stock for each RSU that has been earned and vested, and direct holdings after this grant are reported at 252,948 shares of common stock.
VOLITIONRX LTD President and CEO Cameron John Reynolds reported an equity compensation grant. On February 26, 2026, he was awarded 486,000 restricted stock units (RSUs) under the company’s 2024 Stock Incentive Plan in lieu of cash compensation.
The RSUs will be earned in twelve approximately equal monthly installments starting March 1, 2026, then remain subject to additional time-based vesting in a single installment on February 26, 2027, conditioned on continued service. Once vested and settled, they will convert into an equal number of common shares.
Following this grant, he holds 3,115,547 common shares directly, plus indirect holdings of 1,007,718 shares through Concord International, Inc. and 34,076 shares held by his spouse.
Batchelor Ann-Louise reported acquisition or exercise transactions in this Form 4 filing.
VolitionRx Ltd reported that Group Chief Marketing Officer Ann-Louise Batchelor was granted 142,000 restricted stock units (RSUs) on February 26, 2026 under the company’s 2024 Stock Incentive Plan, in lieu of cash compensation. The RSUs will be earned in twelve roughly equal monthly installments starting March 1, 2026, then vest in a single installment on February 26, 2027, subject to her continued service. Upon vesting and settlement, she will receive one share of common stock for each RSU earned and vested. Following these transactions, she also reports indirect ownership of common stock held by her spouse.
Hughes Terig reported acquisition or exercise transactions in this Form 4 filing.
VOLITIONRX LTD Chief Financial Officer Terig Hughes reported an equity compensation grant rather than a market trade. On February 26, 2026, he was awarded 202,000 restricted stock units (RSUs) under the company’s 2024 Stock Incentive Plan in lieu of cash compensation otherwise owed.
The RSUs will be earned in twelve approximately equal monthly installments starting March 1, 2026. All earned RSUs are then subject to additional time-based vesting in a single installment on February 26, 2027, generally conditioned on Mr. Hughes’ continued service. Upon vesting and settlement, he will receive an equivalent number of common shares.
Rootsaert Rodney Gerard reported acquisition or exercise transactions in this Form 4 filing.
VolitionRx Ltd's secretary, Rodney Gerard Rootsaert, reported an equity compensation grant. He was awarded 119,000 restricted stock units (RSUs) under the 2024 Stock Incentive Plan in lieu of cash compensation. The RSUs are earned in twelve roughly equal monthly installments starting on March 1, 2026.
Once earned, all RSUs are subject to additional time-based vesting in a single installment on February 26, 2027, contingent on his continued service. Following this award, he holds 281,262 shares of common stock directly and has indirect ownership of 1,007,718 shares through Concord International, Inc., where he shares voting and dispositive control.
VolitionRx Ltd reported that General Counsel of Volition Diagnostics, Nicholas Plummer, acquired an award linked to 187,000 restricted stock units (RSUs) on common stock under the company’s 2024 Stock Incentive Plan, in lieu of cash compensation otherwise payable to him.
The RSUs are scheduled to be earned in twelve approximately equal monthly installments starting on March 1, 2026, then subject to additional time-based vesting in a single installment on February 26, 2027, contingent on his continued service. Upon vesting and settlement, he will receive one share of common stock for each earned and vested RSU. Following this award, his directly held common stock position is reported as 420,137 shares.